Gregory Stone, PhD

Director of Microbiology
Pfizer, Inc.

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-1506) In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa Collected from Patients with Presumed Hospital- and Community-acquired Respiratory Tract Infections as a Part of the ATLAS Global Surveillance Program 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1507) In Vitro Activity of Ceftazidime-avibactam against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1508) In Vitro Activity of Aztreonam-avibactam against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1509) In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1510) In Vitro Activity of Ceftibuten-Avibactam and Comparator Agents Against Enterobacterales Collected Globally as Part of the ATLAS Surveillance Program, 2022 by Region
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1513) In Vitro Activity of Ceftaroline against Bacterial Pathogens from Pediatric Patients Collected During the ATLAS Global Surveillance Program in 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT